Appropriate Number of Docetaxel Cycles in Castration-Resistant Prostate Cancer Patients Considering Peripheral Neuropathy and Oncological Control
© 2021 S. Karger AG, Basel..
BACKGROUND: The number of cycles of docetaxel required for castration-resistant prostate cancer (CRPC) is unclear. This study estimated peripheral neuropathy (PN) incidence and the optimal number of treatment cycles in patients receiving docetaxel for CRPC.
PATIENTS AND METHODS: The study retrospectively reviewed 82 patients receiving docetaxel for CRPC at an institution between January 2005 and January 2017. Docetaxel (70 or 75 mg/m2) was administered every 3 weeks, and prednisone 5 mg or dexamethasone 0.5 mg was administered twice a day.
RESULTS: PN (grade ≥2) was noted in 32 (39.0%) patients. The median cumulative dose of docetaxel associated with PN was 675 mg/m2. No factor significantly predicted the occurrence of PN. The prostate-specific antigen progression rate, prostate cancer-specific survival, and overall survival were significantly better with ≥8 cycles of docetaxel than with <8 cycles (p < 0.05).
CONCLUSION: The incidence of PN is high, and 8 treatment cycles are optimal for patients receiving docetaxel for CRPC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:65 |
|---|---|
| Enthalten in: |
Chemotherapy - 65(2020), 5-6 vom: 23., Seite 119-124 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nakai, Yasushi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
15H5577CQD |
|---|
| Anmerkungen: |
Date Completed 30.06.2021 Date Revised 30.06.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1159/000510900 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM320486354 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM320486354 | ||
| 003 | DE-627 | ||
| 005 | 20231225173704.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1159/000510900 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1068.xml |
| 035 | |a (DE-627)NLM320486354 | ||
| 035 | |a (NLM)33486495 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Nakai, Yasushi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Appropriate Number of Docetaxel Cycles in Castration-Resistant Prostate Cancer Patients Considering Peripheral Neuropathy and Oncological Control |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.06.2021 | ||
| 500 | |a Date Revised 30.06.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 S. Karger AG, Basel. | ||
| 520 | |a BACKGROUND: The number of cycles of docetaxel required for castration-resistant prostate cancer (CRPC) is unclear. This study estimated peripheral neuropathy (PN) incidence and the optimal number of treatment cycles in patients receiving docetaxel for CRPC | ||
| 520 | |a PATIENTS AND METHODS: The study retrospectively reviewed 82 patients receiving docetaxel for CRPC at an institution between January 2005 and January 2017. Docetaxel (70 or 75 mg/m2) was administered every 3 weeks, and prednisone 5 mg or dexamethasone 0.5 mg was administered twice a day | ||
| 520 | |a RESULTS: PN (grade ≥2) was noted in 32 (39.0%) patients. The median cumulative dose of docetaxel associated with PN was 675 mg/m2. No factor significantly predicted the occurrence of PN. The prostate-specific antigen progression rate, prostate cancer-specific survival, and overall survival were significantly better with ≥8 cycles of docetaxel than with <8 cycles (p < 0.05) | ||
| 520 | |a CONCLUSION: The incidence of PN is high, and 8 treatment cycles are optimal for patients receiving docetaxel for CRPC | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Castration-resistant | |
| 650 | 4 | |a Docetaxel | |
| 650 | 4 | |a Drug tolerance | |
| 650 | 4 | |a Peripheral neuropathy | |
| 650 | 4 | |a Prostate cancer | |
| 650 | 7 | |a Docetaxel |2 NLM | |
| 650 | 7 | |a 15H5577CQD |2 NLM | |
| 650 | 7 | |a Dexamethasone |2 NLM | |
| 650 | 7 | |a 7S5I7G3JQL |2 NLM | |
| 650 | 7 | |a Prostate-Specific Antigen |2 NLM | |
| 650 | 7 | |a EC 3.4.21.77 |2 NLM | |
| 650 | 7 | |a Prednisone |2 NLM | |
| 650 | 7 | |a VB0R961HZT |2 NLM | |
| 700 | 1 | |a Tanaka, Nobumichi |e verfasserin |4 aut | |
| 700 | 1 | |a Ichikawa, Kazuki |e verfasserin |4 aut | |
| 700 | 1 | |a Miyake, Makito |e verfasserin |4 aut | |
| 700 | 1 | |a Anai, Satoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Fujimoto, Kiyohide |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Chemotherapy |d 1965 |g 65(2020), 5-6 vom: 23., Seite 119-124 |w (DE-627)NLM000137006 |x 1421-9794 |7 nnns |
| 773 | 1 | 8 | |g volume:65 |g year:2020 |g number:5-6 |g day:23 |g pages:119-124 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1159/000510900 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 65 |j 2020 |e 5-6 |b 23 |h 119-124 | ||